摘要
目的观察不同剂量重组人干扰素α-1b雾化吸入治疗毛细支气管炎的疗效及不良反应。方法选取毛细支气管炎患儿109例,随机分为对照组、低剂量组、高剂量组三组,对照组采用常规治疗,高剂量组和低剂量组在对照组基础上分别增加2μg·kg-1·次-1和1μg·kg-1·次-1重组人干扰素α-1b雾化吸入,比较三组的治疗效果。结果高剂量组、低剂量组的痊愈率高于对照组(P<0.05),而高剂量组和低剂量组无统计学差异(P>0.05)。高剂量组、低剂量组的临床症状消失时间、肺功能指标和住院时间均显著优于对照组(P<0.05),而高剂量组和低剂量组无统计学差异(P>0.05)。三组患儿治疗期间均未见严重不良反应。结论增加重组人干扰素α-1b雾化吸入治疗毛细支气管炎的临疗效果显著,且使用低剂量重组人干扰素α-1b更具合理性。
Objective To observe the efficacy and adverse reactions of different doses of recombinant human interferon a-lb for atomization inhalation in the treatment of bronchiolitis. Methods 109 cases of children with bronchiolitis were selected and randomly divided into the control group （routine treatmen0, the low-dose group （routine treatment combined with μg·kg-1recombinant human interferon a-1 b every time for atomization inhalation） and the high-dose group （routine treatment combined with 2μg·kg-1 recombinant human interferon a-lb every time for atomization inhalation）. The curative effects of three groups were compared. Results The cure rate of control group was significantly lower than that of high-dose group and low-dose group （P 〈0.05）, while the high-dose group and low-dose group had no statistical difference （P 〉0.05）. The disappear time of clinical symptoms, pulmonary fimction indicators and length of hospital stay of high-dose group and low-dose group were significantly better than those of control group （P〈0.05）, while the high-dose group and low-dose group had no statistical difference （P〉0.05）. All the three groups had no severe adverse reaction during treatment. Conclusions Additional application of recombinant human interferon a-lb for atomization inhalation has significant clinical efficacy in the treatment of bronchiolitis, and low-dose recombinant human interferon a-lb is more reasonable.
作者
邝绍樑
潘学军
尹少燕
KUANG Shaoliang;PAN Xuejun;YIN Shaoyan(The Fifth People＇s Hospital of Nanhai District, Foshon 528231, China)
出处
《临床医学工程》
2018年第4期455-456,共2页
Clinical Medicine & Engineering
基金
佛山市卫生和计生局医学科研课题"不同剂量重组人干扰素α-1b雾化吸入治疗毛细支气管炎的疗效及不良反应分析"(项目编号:20160188)
